Fate Therapeutics, Inc. (FATE)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.85-11.48%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · FATE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 134.8% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -25.4% |
Growth built into the price is above our model estimate.
The price assumes 160.2 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 117 industry peers
FATE — debt issuance
Dated 2026-11-05
Entry into a Material Definitive Agreement. On November 5, 2026, Fate Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”), with respect to an at-the-market offering program (the “ATM Program”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $100,000,000…
Why it matters: Fate reported $153.8 million in cash and a $21 million quarterly drop. Its stated runway reaches into 2028.
Worry ifFate reports cash and investments below $153.8 million, or cuts its runway estimate to before 2028.
Less concerning ifFate reports cash and investments at or above $153.8 million, while keeping its runway into 2028.
Why it matters: FT839 is a new off-the-shelf cell therapy for autoimmune disease. First dosing would move it from FDA clearance into human testing.
Supportive ifFate reports the first patient dosed in the FT839 Phase 1/2 COMPLETE trial by year-end 2026.
Worry ifFate reports that first dosing has not occurred by year-end 2026, or that the trial start is delayed.
Why it matters: The first RECLAIM-LN patient went home the same day. More safe outpatient treatments would support broad access to this therapy.
Supportive ifFate reports more RECLAIM-LN patients treated as outpatients, with no serious safety issue that stops dosing.
Worry ifFate reports a serious safety issue linked to treatment or pauses dosing in RECLAIM-LN.
Why it matters: The trial aims to enroll about 53 patients by the first half of 2028. On-time enrollment would support the FT819 path.
Supportive ifOn November 12, Fate reports new patients dosed or screened at active sites. Enrollment remains on pace for the first half of 2028.
Worry ifFate reports no new patients dosed or screened, or says enrollment will finish after the first half of 2028.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$232 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $794 loss on $10,000 · 7.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,244 loss on $10,000 · 42.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Complete renal response at Week 26 is RECLAIM-LN's main test. A clear response would support further development of FT819.
Supportive ifWhen Week 26 results are reported, the trial meets its stated primary endpoint for complete renal response.
Worry ifWhen Week 26 results are reported, the trial misses its primary endpoint for complete renal response.